Fenbendazole for humans is widely used as a veterinary medicine, and it has been shown to have antiparasitic effects in various animal species. However, its safety and effectiveness in human patients for sustained periods of time has not been thoroughly studied yet. The drug is marketed under the names Safe-Guard and Panacur, among others.

It has been shown to interfere with the ability of cancer cells to absorb glucose, which is essential for their growth and proliferation. This starves cancer cells of the energy they need, and results in their death. This has been demonstrated in both in vitro experiments and in live patient cases.

The use of fenbendazole for cancer treatment has also been reported to boost the effectiveness of other chemotherapy drugs, such as the taxanes and vinca alkaloids. These findings suggest that fenbendazole may act as a synergist in combination with other treatments, such as the oxaliplatin-based fluorouracil regimen for colon cancer.

Our laboratory studies of EMT6 tumor-bearing mice have shown that three daily i.p. injections of fenbendazole (50 mg/kg/day) does not inhibit the growth of these tumors, either alone or in combination with 10 Gy of x-rays (Figure 3).

This is consistent with earlier experiments, in which we found that fenbendazole does not significantly affect the radiation response of hypoxic cells, even at higher concentrations. The experiments were performed in cultures sealed with rubber gaskets, needles for the influx and efflux of gases, and gassed with 95% nitrogen/5% CO2 at 1 ppm oxygen, to simulate conditions encountered in 5-fluorouracil-resistant SNU-C5 cells. fenbendazole for humans